Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pirow Bekker

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology in Drug Development|July 12, 2024
Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy ParticipantsShichang Miao, Pirow Bekker, Danielle Armas, et al.
The Lancet. Rheumatology|January 22, 2024
Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trialNaomi J Patel, David R W Jayne, Peter A Merkel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Serum osteoprotegerin levels in healthy controls and cancer patientsAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Kidney International Reports|April 18, 2023
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of AvacopanFrank B Cortazar, John L Niles, David R W Jayne, et al.
Annals of the Rheumatic Diseases|May 17, 2012
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trialPaul P Tak, Andra Balanescu, Vira Tseluyko, et al.
ACR Open Rheumatology|October 31, 2020
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated VasculitisPeter A Merkel, John Niles, Richard Jimenez, et al.
The Lancet. Diabetes & Endocrinology|August 14, 2015
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trialDick de Zeeuw, Pirow Bekker, Elena Henkel, et al.
Current Drug Metabolism|October 15, 2025
Mass Balance and Metabolic Profiling of Avacopan, a Selective C5a Receptor 1 Antagonist, in Healthy HumansYang Song, Shichang Miao, Ruiping Zhao, et al.
Seminars in Arthritis and Rheumatism|December 6, 2022
Corrigendum to The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time [Seminars in Arthritis and Rheumatism Volume 55, 152010]John H Stone, P Jane McDowell, David R W Jayne, et al.
Seminars in Arthritis and Rheumatism|July 2, 2024
Corrigendum to "The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time" [Seminars in Arthritis and Rheumatism 55 (2022):152010]John H Stone, P Jane McDowell, David R W Jayne, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|July 12, 2024
Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy ParticipantsShichang Miao, Pirow Bekker, Danielle Armas, et al.
The Lancet. Rheumatology|January 22, 2024
Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trialNaomi J Patel, David R W Jayne, Peter A Merkel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Serum osteoprotegerin levels in healthy controls and cancer patientsAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Kidney International Reports|April 18, 2023
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of AvacopanFrank B Cortazar, John L Niles, David R W Jayne, et al.
Annals of the Rheumatic Diseases|May 17, 2012
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trialPaul P Tak, Andra Balanescu, Vira Tseluyko, et al.
ACR Open Rheumatology|October 31, 2020
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated VasculitisPeter A Merkel, John Niles, Richard Jimenez, et al.
The Lancet. Diabetes & Endocrinology|August 14, 2015
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trialDick de Zeeuw, Pirow Bekker, Elena Henkel, et al.
Current Drug Metabolism|October 15, 2025
Mass Balance and Metabolic Profiling of Avacopan, a Selective C5a Receptor 1 Antagonist, in Healthy HumansYang Song, Shichang Miao, Ruiping Zhao, et al.
Seminars in Arthritis and Rheumatism|December 6, 2022
Corrigendum to The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time [Seminars in Arthritis and Rheumatism Volume 55, 152010]John H Stone, P Jane McDowell, David R W Jayne, et al.
Seminars in Arthritis and Rheumatism|July 2, 2024
Corrigendum to "The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time" [Seminars in Arthritis and Rheumatism 55 (2022):152010]John H Stone, P Jane McDowell, David R W Jayne, et al.
Pageof 3